Follicular Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EZH2 p.Y646N | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646F | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646H | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646S | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646C | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A862G | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A692V | Follicular Lymphoma | Tazemetostat | |
| HSE (1) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine | |
| HSE (1) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine | |
| HSE (1) | CD20 + | Follicular Lymphoma | Chlorambucil, Mitoxantrone, Prednisolone, Rituximab | |
| HSE (1) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab | |
| HSE (4) | CD20 + | Follicular Lymphoma | Rituximab |